EVERREST prospective study: a 6-year prospective study to define the clinical and biological characteristics of pregnancies affected by severe early onset fetal growth restriction

Rebecca Spencer, Gareth Ambler, Jana Brodszki, Anke Diemert, Francesc Figueras, Eduard Gratacós, Stefan R Hansson, Kurt Hecher, Angela Huertas-Ceballos, Neil Marlow, Karel Marsál, Eva Morsing, Donald Peebles, Carlo Rossi, Neil J Sebire, John F Timms, Anna L David, EVERREST Consortium, Rebecca Spencer, Gareth Ambler, Jana Brodszki, Anke Diemert, Francesc Figueras, Eduard Gratacós, Stefan R Hansson, Kurt Hecher, Angela Huertas-Ceballos, Neil Marlow, Karel Marsál, Eva Morsing, Donald Peebles, Carlo Rossi, Neil J Sebire, John F Timms, Anna L David, EVERREST Consortium

Abstract

Background: Fetal growth restriction (FGR) is a serious obstetric condition for which there is currently no treatment. The EVERREST Prospective Study has been designed to characterise the natural history of pregnancies affected by severe early onset FGR and establish a well phenotyped bio-bank. The findings will provide up-to-date information for clinicians and patients and inform the design and conduct of the EVERREST Clinical Trial: a phase I/IIa trial to assess the safety and efficacy of maternal vascular endothelial growth factor (VEGF) gene therapy in severe early onset FGR. Data and samples from the EVERREST Prospective Study will be used to identify ultrasound and/or biochemical markers of prognosis in pregnancies with an estimated fetal weight (EFW) <3rd centile between 20+0 and 26+6 weeks of gestation.

Methods: This is a 6 year European multicentre prospective cohort study, recruiting women with a singleton pregnancy where the EFW is <3rd centile for gestational age and <600 g at 20+0 to 26+6 weeks of gestation. Detailed data are collected on: maternal history; antenatal, peripartum, and postnatal maternal complications; health economic impact; psychological impact; neonatal condition, progress and complications; and infant growth and neurodevelopment to 2 years of corrected age in surviving infants. Standardised longitudinal ultrasound measurements are performed, including: fetal biometry; uterine artery, umbilical artery, middle cerebral artery, and ductus venosus Doppler velocimetry; and uterine artery and umbilical vein volume blood flow. Samples of maternal blood and urine, amniotic fluid (if amniocentesis performed), placenta, umbilical cord blood, and placental bed (if caesarean delivery performed) are collected for bio-banking. An initial analysis of maternal blood samples at enrolment is planned to identify biochemical markers that are predictors for fetal or neonatal death.

Discussion: The findings of the EVERREST Prospective Study will support the development of a novel therapy for severe early onset FGR by describing in detail the natural history of the disease and by identifying women whose pregnancies have the poorest outcomes, in whom a therapy might be most advantageous. The findings will also enable better counselling of couples with affected pregnancies, and provide a valuable resource for future research into the causes of FGR.

Trial registration: NCT02097667 registered 31st October 2013.

Keywords: Angiogenic; Doppler ultrasound; Fetal growth restriction; Outcome; Placental insufficiency; Prediction; Prospective cohort; Ultrasound biometry; Uteroplacental.

Figures

Fig. 1
Fig. 1
Participant timelines for the EVERREST Prospective Study

References

    1. Lawn JE, Blencowe H, Pattinson R, Cousens S, Kumar R, Ibiebele I, et al. Stillbirths: Where? When? Why? How to make the data count? Lancet. 2011;377(9775):1448–1463. doi: 10.1016/S0140-6736(10)62187-3.
    1. Spencer RN, Carr DJ, David AL. Treatment of poor placentation and the prevention of associated adverse outcomes - what does the future hold? Prenat Diagn. 2014;34(7):677–684.
    1. Marlow N, Wolke D, Bracewell MA, Samara M. Neurologic and developmental disability at six years of age after extremely preterm birth. N Engl J Med. 2005;352(1):9–19. doi: 10.1056/NEJMoa041367.
    1. Brodszki J, Morsing E, Malcus P, Thuring A, Ley D, Marsal K. Early intervention in management of very preterm growth-restricted fetuses: 2-year outcome of infants delivered on fetal indication before 30 gestational weeks. Ultrasound Obstet Gynecol. 2009;34(3):288–296. doi: 10.1002/uog.7321.
    1. Morsing E, Asard M, Ley D, Stjernqvist K, Marsal K. Cognitive function after intrauterine growth restriction and very preterm birth. Pediatrics. 2011;127(4):e874–e882. doi: 10.1542/peds.2010-1821.
    1. Khong TY, Mooney EE, Ariel I, Balmus NC, Boyd TK, Brundler MA, et al. Sampling and definitions of placental lesions: Amsterdam Placental Workshop Group Consensus Statement. Arch Pathol Lab Med. 2016;140(7):698-713.
    1. Brownbill P, Mills TA, Soydemir DF, Sibley CP. Vasoactivity to and endogenous release of vascular endothelial growth factor in the in vitro perfused human placental lobule from pregnancies complicated by preeclampsia. Placenta. 2008;29(11):950–955. doi: 10.1016/j.placenta.2008.08.020.
    1. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111(5):649–658. doi: 10.1172/JCI17189.
    1. Savvidou MD, Yu CK, Harland LC, Hingorani AD, Nicolaides KH. Maternal serum concentration of soluble fms-like tyrosine kinase 1 and vascular endothelial growth factor in women with abnormal uterine artery Doppler and in those with fetal growth restriction. Am J Obstet Gynecol. 2006;195(6):1668–1673. doi: 10.1016/j.ajog.2006.03.065.
    1. Bersinger NA, Odegard RA. Serum levels of macrophage colony stimulating, vascular endothelial, and placenta growth factor in relation to later clinical onset of pre-eclampsia and a small-for-gestational age birth. Am J Reprod Immunol. 2005;54(2):77–83. doi: 10.1111/j.1600-0897.2005.00290.x.
    1. David AL, Torondel B, Zachary I, Wigley V, Abi-Nader K, Mehta V, et al. Local delivery of VEGF adenovirus to the uterine artery increases vasorelaxation and uterine blood flow in the pregnant sheep. Gene Ther. 2008;15(19):1344–1350. doi: 10.1038/gt.2008.102.
    1. Mehta V, Abi-Nader KN, Peebles DM, Benjamin E, Wigley V, Torondel B, et al. Long-term increase in uterine blood flow is achieved by local overexpression of VEGF-A(165) in the uterine arteries of pregnant sheep. Gene Ther. 2012;19(9):925–935. doi: 10.1038/gt.2011.158.
    1. Mehta V, Abi-Nader KN, Shangaris P, Shaw SW, Filippi E, Benjamin E, et al. Local over-expression of VEGF-DΔNΔC in the uterine arteries of pregnant sheep results in long-term changes in uterine artery contractility and angiogenesis. PLoS One. 2014;9(6):e100021. doi: 10.1371/journal.pone.0100021.
    1. Carr D, Wallace JM, Aitken RP, Milne JS, Mehta V, Martin JF, et al. Uteroplacental adenovirus VEGF gene therapy increases fetal growth velocity in growth-restricted sheep pregnancies. Hum Gene Ther. 2014;25(4):375–384. doi: 10.1089/hum.2013.214.
    1. Swanson A, Rossi C, Ofir K, Mehta V, Boyd M, Barker H, et al. Maternal therapy with Ad.VEGF-A165 increases fetal weight at term in a guinea pig model of fetal growth restriction. Hum Gene Ther. 2016;27(12):997–1007.
    1. Hecher K, Bilardo CM, Stigter RH, Ville Y, Hackeloer BJ, Kok HJ, et al. Monitoring of fetuses with intrauterine growth restriction: a longitudinal study. Ultrasound Obstet Gynecol. 2001;18(6):564–570. doi: 10.1046/j.0960-7692.2001.00590.x.
    1. Unterscheider J, Daly S, Geary MP, Kennelly MM, McAuliffe FM, O’Donoghue K, et al. Optimizing the definition of intrauterine growth restriction: the multicenter prospective PORTO Study. Am J Obstet Gynecol. 2013;208(4):290 e1-6.
    1. Bilardo CM, Wolf H, Stigter RH, Ville Y, Baez E, Visser GH, et al. Relationship between monitoring parameters and perinatal outcome in severe, early intrauterine growth restriction. Ultrasound Obstet Gynecol. 2004;23(2):119–125. doi: 10.1002/uog.965.
    1. Baschat AA, Cosmi E, Bilardo CM, Wolf H, Berg C, Rigano S, et al. Predictors of neonatal outcome in early-onset placental dysfunction. Obstet Gynecol. 2007;109(2 Pt 1):253–261. doi: 10.1097/01.AOG.0000253215.79121.75.
    1. Odibo AO, Goetzinger KR, Cahill AG, Odibo L, Macones GA. Combined sonographic testing index and prediction of adverse outcome in preterm fetal growth restriction. Am J Perinatol. 2014;31(2):139–44.
    1. Lawin-O’Brien AR, Dall’Asta A, Knight C, Sankaran S, Scala C, Khalil A, et al. Short term outcome of Periviable SGA: Is our counseling up to date? Ultrasound Obstet Gynecol. 2016;48(5):636–641.
    1. Lees C, Marlow N, Arabin B, Bilardo CM, Brezinka C, Derks JB, et al. Perinatal morbidity and mortality in early-onset fetal growth restriction: cohort outcomes of the trial of randomized umbilical and fetal flow in Europe (TRUFFLE) Ultrasound Obstet Gynecol. 2013;42(4):400–408. doi: 10.1002/uog.13190.
    1. Lees CC, Marlow N, van Wassenaer-Leemhuis A, Arabin B, Bilardo CM, Brezinka C, et al. 2 year neurodevelopmental and intermediate perinatal outcomes in infants with very preterm fetal growth restriction (TRUFFLE): a randomised trial. Lancet. 2015;385(9983):2162–72.
    1. Spencer R, Carr D, David A. Short-term outcome after antenatal diagnosis of severe early-onset fetal growth restriction. BJOG. 2015;122(S2):73.
    1. Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007;4(10):e297. doi: 10.1371/journal.pmed.0040297.
    1. The PLOS Medicine Editors Observational studies: getting clear about transparancy. PLoS Med. 2014;11(8):e1001711. doi: 10.1371/journal.pmed.1001711.
    1. Carvalho MHB, Brizot ML, Lopes LM, Chiba CH, Miyadahira S, Zugaib M. Detection of fetal structural abnormalities at the 11–14 week ultrasound scan. Prenat Diagn. 2002;22(1):1–4. doi: 10.1002/pd.200.
    1. Myatt L, Redman CW, Staff AC, Hansson S, Wilson ML, Laivuori H, et al. Strategy for standardization of preeclampsia research study design. Hypertension. 2014;63(6):1293–1301. doi: 10.1161/HYPERTENSIONAHA.113.02664.
    1. Salomon LJ, Alfirevic Z, Berghella V, Bilardo C, Hernandez-Andrade E, Johnsen SL, et al. Practice guidelines for performance of the routine mid-trimester fetal ultrasound scan. Ultrasound Obstet Gynecol. 2011;37(1):116–126. doi: 10.1002/uog.8831.
    1. McKelvey A, Pateman K, Balchin I, Peebles DM, Rodeck CH, David AL. Total uterine artery blood volume flow rate in nulliparous women (TVFR) is associated with birthweight and gestation at delivery. Ultrasound Obstet Gynecol. 2017;49(1):54–60.
    1. Acharya G, Wilsgaard T, Rosvold Berntsen GK, Maltau JM, Kiserud T. Reference ranges for umbilical vein blood flow in the second half of pregnancy based on longitudinal data. Prenat Diagn. 2005;25(2):99–111. doi: 10.1002/pd.1091.
    1. Meades R, Ayers S. Anxiety measures validated in perinatal populations: a systematic review. J Affect Disord. 2011;133(1–2):1–15. doi: 10.1016/j.jad.2010.10.009.
    1. Costeloe K, Hennessy E, Gibson AT, Marlow N, Wilkinson AR. The EPICure study: outcomes to discharge from hospital for infants born at the threshold of viability. Pediatrics. 2000;106(4):659–671. doi: 10.1542/peds.106.4.659.
    1. Callahan JL, Borja SE. Psychological outcomes and measurement of maternal posttraumatic stress disorder during the perinatal period. J Perinat Neonatal Nurs. 2008;22(1):49–59. doi: 10.1097/01.JPN.0000311875.38452.26.
    1. Newman E, Willard T, Sinclair R, Kaloupek D. Empirically supported ethical research practice: the costs and benefits of research from the participants’ view. Accountability in Research. 2001;8(4):309–329. doi: 10.1080/08989620108573983.
    1. Cohen J. Statistical Power analysis for behavioural sciences. 2nd ed. Hillsdale: Lawrence Erlbaum Associates; 1988.
    1. David A, Thornton S, Sutcliffe A, Williams P. Scientific impact paper No. 50. Developing new pharmaceutical treatments for obstetric conditions. London: RCOG; 2015.
    1. Gordijn SJ, Beune IM, Thilaganathan B, Papageorghiou A, Baschat AA, Baker PN, et al. Consensus definition for placental fetal growth restriction: a Delphi procedure. Ultrasound Obstet Gynecol. 2016;48(3):333–9.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa